Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ZymoGenetics Furthers Bristol's "Multi-Pronged" Approach To HCV, Sigal Says

This article was originally published in The Pink Sheet Daily

Executive Summary

R&D President Sigal talks about how the acquisition of ZymoGenetics fits into Bristol's research strategy in his first public comments to investors since March.

You may also be interested in...



Bristol, Pharmasset To Study Oral HCV Regimen Together

Partnership to study Bristol's NS5A inhibitor with Pharmasset's polymerase inhibitor is the first cross-company collaboration to study two oral agents in hepatitis C.

Bristol, Pharmasset To Study Oral HCV Regimen Together

Partnership to study Bristol's NS5A inhibitor with Pharmasset's polymerase inhibitor is the first cross-company collaboration to study two oral agents in hepatitis C.

From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics

Ever since its pure-play biopharma strategy went into effect, Bristol-Myers Squibb has preferred buying biotechs it knows well. Hepatitis C development partner ZymoGenetics is no exception.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel